<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30796822</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1945-2403</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of analytical toxicology</Title>
          <ISOAbbreviation>J Anal Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Demoxepam Derivatization and GC-MS Analysis Produces Erroneous Nordiazepam and Oxazepam Results.</ArticleTitle>
        <Pagination>
          <StartPage>406</StartPage>
          <EndPage>410</EndPage>
          <MedlinePgn>406-410</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/jat/bkz006</ELocationID>
        <Abstract>
          <AbstractText>Demoxepam, when derivatized by silylation and analyzed using gas chromatography-mass spectrometry (GC-MS), produces artifacts which are falsely identified as nordiazepam and oxazepam. Demoxepam was analyzed unextracted at various concentrations, using different derivatization procedures, and on different GC-MS systems. Oxazepam and nordiazepam were consistently identified in neat demoxepam samples, despite the changing variables. Under certain conditions, oxazepam was identified as low as 50 ng/mL derivatized demoxepam, and nordiazepam identified as low as 500 ng/mL derivatized demoxepam. The analysis of underivatized demoxepam resulted in nordiazepam detection at levels ≥2,500 ng/mL, whereas oxazepam was not detectable at or below 10,000 ng/mL demoxepam. Isolating the derivatization procedures and GC-MS analyses demonstrates that these processes are responsible for any degradation or rearrangement reactions which are taking place. Laboratories which follow similar procedures for benzodiazepine confirmations should consider these findings when interpreting analytical data from chlordiazepoxide cases.</AbstractText>
          <CopyrightInformation>© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sarris</LastName>
            <ForeName>Gregory G</ForeName>
            <Initials>GG</Initials>
            <AffiliationInfo>
              <Affiliation>New York State Police Forensic Investigation Center, 1220 Washington Ave, Bldg 30, Albany, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Limoges</LastName>
            <ForeName>Jennifer F</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
              <Affiliation>New York State Police Forensic Investigation Center, 1220 Washington Ave, Bldg 30, Albany, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Anal Toxicol</MedlineTA>
        <NlmUniqueID>7705085</NlmUniqueID>
        <ISSNLinking>0146-4760</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>12794-10-4</RegistryNumber>
          <NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>67220MCM01</RegistryNumber>
          <NameOfSubstance UI="D003708">Nordazepam</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6GOW6DWN2A</RegistryNumber>
          <NameOfSubstance UI="D010076">Oxazepam</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6RZ6XEZ3CR</RegistryNumber>
          <NameOfSubstance UI="D002707">Chlordiazepoxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8X1XP5M0SB</RegistryNumber>
          <NameOfSubstance UI="C000869">demoxepam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002707" MajorTopicYN="N">Chlordiazepoxide</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008401" MajorTopicYN="N">Gas Chromatography-Mass Spectrometry</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057230" MajorTopicYN="N">Limit of Detection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003708" MajorTopicYN="N">Nordazepam</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010076" MajorTopicYN="N">Oxazepam</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30796822</ArticleId>
        <ArticleId IdType="doi">10.1093/jat/bkz006</ArticleId>
        <ArticleId IdType="pii">5363996</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
